Key Takeaway
About the GLP-1 GIP glucagon difference is key to making sense of the next wave of weight management medications. Each of these hormones plays a unique role in how your body handles hunger, blood sugar, and energy use.
About the GLP-1 GIP glucagon difference is key to making sense of the next wave of weight management medications. Each of these hormones plays a unique role in how your body handles hunger, blood sugar, and energy use. And the medications that target more than one of them tend to deliver stronger results.
Key Takeaways: - GLP-1: The Appetite Controller - GIP: The Metabolic Amplifier - Glucagon: The Energy Burner - Discover why multi-agonists work better
This is not just science for the sake of science. Knowing how these targets work helps you have better conversations with your provider about which treatment is right for you.
GLP-1: The Appetite Controller
GLP-1 stands for glucagon-like peptide-1. Your gut produces it naturally after you eat. It does several things at once.
First, it tells your brain you are full. GLP-1 activates satiety centers in the hypothalamus, which reduces your desire to keep eating. This is the primary mechanism behind the appetite suppression people experience on GLP-1 medications.
Second, it slows gastric emptying. Food stays in your stomach longer, which means you feel full for a longer period after meals. This is also why some people experience nausea when starting treatment. Your stomach is not emptying as quickly as it used to.
"The conversation about obesity needs to shift from willpower to biology. These medications work because obesity is a neuroendocrine disease, not a character flaw.") Dr. Fatima Cody Stanford, MD, MPH, Massachusetts General Hospital
Third, GLP-1 improves insulin secretion. When your blood sugar rises after a meal, GLP-1 signals your pancreas to release more insulin. It does this in a glucose-dependent way, meaning it does not cause dangerously low blood sugar on its own.
Medications like compounded semaglutide target the GLP-1 receptor. They produce significant weight loss, typically around 15% of body weight in clinical trials. Learn more in our .
GIP: The Metabolic Amplifier
GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it is an incretin hormone released by your gut after eating. But it works through different pathways.
Free Download: GLP-1 Medication Comparison One-Pager See how single, dual, and triple agonist drugs compare in one easy-to-read chart. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
GIP also stimulates insulin release from the pancreas. But beyond that, it appears to play a role in how your body stores and processes fat. Research suggests GIP receptor activation may improve how fat tissue functions, making it more metabolically healthy.
GIP also acts on the brain. Studies show GIP receptor activation in the central nervous system contributes to reduced food intake. This adds to the appetite suppression already provided by GLP-1.
Tirzepatide is the best-known dual GLP-1/GIP agonist. By hitting both targets, it produced about 22% weight loss in clinical trials, which was significantly more than GLP-1 alone. The combination appears to amplify the weight loss effect beyond what either hormone achieves on its own.
For a comparison of these medications, check out our .
Glucagon: The Energy Burner
Glucagon is the third piece of the puzzle. Produced by your pancreas, glucagon does the opposite of insulin in many ways. It raises blood sugar by telling your liver to release stored glucose. But it also does something critical for weight management: it increases energy expenditure.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →When glucagon receptors are activated, your body burns more calories at rest. It promotes the breakdown of fat in the liver, which is why glucagon-targeting drugs show strong improvements in fatty liver disease. It may also promote thermogenesis, the process of generating heat from stored energy.
The challenge with glucagon is that activating it alone would raise blood sugar, which is the opposite of what you want in a diabetes or weight management drug. That is why it is always combined with GLP-1. The GLP-1 component handles blood sugar control while glucagon boosts energy expenditure and fat burning.
Retatrutide is the first triple agonist (GLP-1/GIP/glucagon) in clinical trials. It showed 24% weight loss in Phase 2, the highest of any weight management drug studied to date.
Why Multi-Agonists Work Better
The logic behind multi-agonist drugs is straightforward. Each hormone target contributes a different mechanism to weight loss. When you combine them, you get complementary effects that add up to more than any single target delivers.
GLP-1 reduces appetite and improves blood sugar. GIP amplifies metabolic improvements and adds to appetite suppression. Glucagon increases calorie burning and promotes fat breakdown.
Think of it like a three-pronged approach. You eat less (GLP-1 + GIP), your metabolism works better (GIP), and you burn more energy at rest (glucagon). The clinical data supports this theory. Single agonists produce about 15% weight loss. Dual agonists produce about 22%. Triple agonists have shown about 24%.
This progression is why the pharmaceutical industry is investing heavily in multi-agonist drugs. The future of weight management may involve medications that activate three, four, or even more hormone pathways simultaneously.
But the medications available today already deliver life-changing results for most people. If you are ready to start, FormBlends providers can help you choose the right option.
Frequently Asked Questions
What is the difference between GLP-1 and GIP?
Both are incretin hormones that reduce appetite and improve blood sugar. GLP-1 primarily slows gastric emptying and activates brain satiety centers. GIP appears to amplify metabolic improvements and may improve fat tissue function. Together, they produce more weight loss than either alone.
Why does glucagon help with weight loss?
Glucagon increases energy expenditure, meaning your body burns more calories at rest. It also promotes fat breakdown in the liver. When combined with GLP-1 (which prevents blood sugar from rising too high), glucagon adds a calorie-burning effect on top of appetite reduction.
What is a triple agonist?
A triple agonist is a medication that activates three hormone receptors simultaneously. Retatrutide, for example, targets GLP-1, GIP, and glucagon receptors. This multi-target approach may produce greater weight loss than drugs targeting only one or two receptors.
Which GLP-1 medication targets the most receptors?
Retatrutide targets three receptors (GLP-1, GIP, glucagon), making it the most broadly acting GLP-1 drug in clinical development. It is not yet FDA-approved. Currently available options include single-agonists like semaglutide and dual-agonists like tirzepatide.
Should I choose a single or dual agonist?
This depends on your individual health profile and goals. Both options produce meaningful weight loss. A licensed provider can evaluate your needs and recommend the best fit. to explore your options.
Start your goals Today
Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you, consultations are free and confidential.
Sources & References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
Nothing in this article should be construed as medical advice. The information provided is educational only. Always consult with your healthcare provider before beginning, modifying, or discontinuing any medication or treatment. FormBlends connects patients with licensed providers for individualized care.
Last updated: 2026-03-24